Seyed Hossein Shahcheraghi | Molecular Pharmacology | Innovative Molecular Biologist Award

Published on by Molecular Biologist

Innovative Molecular Biologist Award

Seyed Hossein Shahcheraghi
Yazd Shahid Sadoughi University of Medical Sciences Campus, Iran

Seyed Hossein Shahcheraghi
Affiliation Yazd Shahid Sadoughi University of Medical Sciences Campus
Country Iran
Scopus ID 55935316300
Documents 75
Citations 820
h-index 13
Subject Area Molecular Pharmacology
Event International Molecular Biologist Awards
ORCID 0000-0003-1399-5222

Seyed Hossein Shahcheraghi is a researcher affiliated with Yazd Shahid Sadoughi University of Medical Sciences Campus in Iran, with a stated subject-area focus in molecular pharmacology. These bibliometric indicators provide a quantitative overview of the research record and are presented here as profile information rather than as an independent assessment of scientific quality.[1] [2]

Abstract

This academic recognition profile presents the research record of Seyed Hossein Shahcheraghi, affiliated with Yazd Shahid Sadoughi University of Medical Sciences Campus, Iran. The stated research subject area is molecular pharmacology, a field concerned with molecular and cellular mechanisms underlying pharmacological activity, drug action, and therapeutic response. The available Scopus profile reports 75 documents, 820 citations, and an h-index of 13.[1] The profile is additionally associated with ORCID identifier 0000-0003-1399-5222.[2] On the basis of the supplied bibliometric information and stated research area, the researcher is presented in connection with the Innovative Molecular Biologist Award under the International Molecular Biologist Awards.

Keywords

Keywords: Seyed Hossein Shahcheraghi; Molecular Pharmacology; Molecular Biology; Pharmacology; Biomedical Research; Research Impact; Bibliometrics; Scopus; ORCID; Innovative Molecular Biologist Award.

Introduction

Molecular pharmacology examines pharmacological phenomena at the molecular and cellular levels, linking biological mechanisms with the actions of drugs and other bioactive compounds. Modern pharmacological research increasingly incorporates molecular targets, signaling pathways, cellular responses, and mechanisms that influence therapeutic activity. The identification and characterization of molecular targets are consequently important components of contemporary drug discovery and pharmacological investigation.[4]

Within this broader scientific context, the research profile of Seyed Hossein Shahcheraghi is identified with molecular pharmacology and is associated with Yazd Shahid Sadoughi University of Medical Sciences Campus in Iran. The bibliographic indicators supplied for the profile provide a measurable description of publication activity and citation influence within indexed scholarly literature.[1]

Research Profile

The researcher’s stated subject area is Molecular Pharmacology. The supplied Scopus information identifies the researcher with Author ID 55935316300 and records 75 documents, 820 citations, and an h-index of 13.[1] These values are bibliometric descriptors of the indexed research record and may change as additional publications and citations are incorporated into bibliographic databases.

  • Researcher: Seyed Hossein Shahcheraghi
  • Institution: Yazd Shahid Sadoughi University of Medical Sciences Campus
  • Country: Iran
  • Primary subject area: Molecular Pharmacology
  • Scopus documents: 75
  • Scopus citations: 820
  • h-index: 13
  • ORCID: 0000-0003-1399-5222

The ORCID identifier provides a persistent researcher identifier intended to support reliable attribution of scholarly works and distinguish researchers across systems.[2] Used alongside bibliographic identifiers such as Scopus Author ID, persistent identifiers can assist in organizing and validating scholarly records.

Research Contributions

The available information places Shahcheraghi’s research within molecular pharmacology. At this level of description, the most appropriate characterization is a field-based one rather than a claim concerning a particular molecular pathway, therapeutic target, disease model, or individual discovery, because those details are not specified in the supplied researcher profile.

Molecular pharmacology encompasses the study of interactions between pharmacologically active molecules and biological systems. Research in this area may connect molecular targets with cellular mechanisms and pharmacological outcomes, contributing to the broader understanding of drug action and therapeutic development.[4] The researcher’s stated subject-area classification therefore provides the principal basis for describing the scientific domain represented in this recognition profile.

Publications

The supplied bibliometric record reports 75 documents indexed under the researcher’s Scopus Author ID. This publication count represents the document total provided for the profile at the time of preparation and should be understood as a database-derived indicator rather than a complete independent bibliography of every scholarly work associated with the researcher.[1]

A publication-level assessment would ordinarily examine article titles, journals, publication dates, co-authorship, citation patterns, research topics, and persistent identifiers such as DOI records. No individual publication list or researcher-specific DOI information was supplied for this page; therefore, no specific article is attributed to Shahcheraghi without an independently verified bibliographic record.

Research Impact

The supplied Scopus profile reports 820 citations and an h-index of 13.[1] Citation counts provide one quantitative measure of how frequently indexed scholarly documents have been cited, while the h-index combines publication and citation information into a single bibliometric indicator. Such measures are useful for describing research visibility but do not, by themselves, establish the quality, originality, or practical significance of individual research contributions.

The reported document and citation figures provide a quantitative basis for recognizing an established publication record within indexed literature. They should nevertheless be interpreted in relation to disciplinary practices, publication age, database coverage, authorship patterns, and other qualitative evidence when making a comprehensive assessment of research influence.

Award Suitability

The profile is presented in connection with the Innovative Molecular Biologist Award under the International Molecular Biologist Awards. The stated field of Molecular Pharmacology provides a direct connection to molecular-level biological research, while the reported Scopus record supplies quantitative evidence of sustained scholarly publication and citation activity.[1]

On the information provided, the recognition profile can be framed around three principal elements: an identified academic affiliation, a defined molecular pharmacology subject area, and a documented bibliometric record. The award suitability statement is therefore descriptive of the supplied profile and does not constitute an independent peer-review judgment or a claim of comparative superiority over other researchers.

Conclusion

Seyed Hossein Shahcheraghi is identified with Yazd Shahid Sadoughi University of Medical Sciences Campus, Iran, and with the research area of Molecular Pharmacology. The supplied Scopus profile reports 75 documents, 820 citations, and an h-index of 13, while ORCID provides the persistent identifier 0000-0003-1399-5222.[1] [2]

These identifiers and bibliometric indicators establish the principal factual basis of this academic recognition page. In the context of the International Molecular Biologist Awards, the profile supports presentation under the Innovative Molecular Biologist Award while maintaining a distinction between documented bibliometric information and broader qualitative judgments concerning scientific achievement.

References

  1. Elsevier. (n.d.). Scopus author details: Seyed Hossein Shahcheraghi, Author ID 55935316300. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=55935316300
  2. ORCID. (n.d.). Seyed Hossein Shahcheraghi — ORCID record. ORCID.
    https://orcid.org/0000-0003-1399-5222
  3. International Molecular Biologist Awards. (n.d.). International Molecular Biologist Awards.
    https://molecularbiologist.org/
  4. Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., & Overington, J. P. (2017). A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery, 16, 19–34.
    https://doi.org/10.1038/nrd.2016.230
  5. Molecular pharmacology and drug-target research. DOI-linked scholarly literature concerning molecular drug targets and pharmacological mechanisms.
    https://doi.org/10.1038/nrd.2016.116

Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award

Published on by Molecular Biologist

Dr. Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award 

Scientific Research Lead | Memorial Sloan Kettering Cancer Center | United States

Dr. Ingrid Tatiana Erazo is a distinguished cancer researcher and Scientific Research Lead at Memorial Sloan Kettering Cancer Center (MSKCC) with extensive experience in translational oncology. She earned her PhD Summa Cum Laude in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, where she pioneered research on the ERK5 signaling pathway. Her early postdoctoral work led to the discovery of the mechanism of action for ABTL-0812, an autophagy-inducing anticancer agent now in Phase III clinical trials. Over the past decade at MSKCC, she has advanced understanding of PRMT5 inhibition, therapeutic resistance, and biomarker development for precision oncology. She currently leads initiatives integrating liquid biopsy diagnostics for early cancer detection and is spearheading global health equity programs, including the creation of Brazil’s first national referral network for cancer clinical trials. Her work bridges molecular discoveries with clinical application, driving advancements in both targeted therapies and diagnostic tools.

Professional Profile

Scopus

ORCID

Google Scholar

Education

Dr. Erazo earned her PhD in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, graduating Summa Cum Laude. Her doctoral research focused on dissecting the ERK5 signaling pathway and its role in cancer cell proliferation and survival. She used Tandem Affinity Purification to map ERK5’s interactome, uncovering novel noncanonical mechanisms and post-translational modifications such as SUMOylation that opened new therapeutic opportunities. Collaborating with Dana-Farber Cancer Institute at Harvard, she co-developed potent and selective ERK5 inhibitors, providing valuable pharmacological tools for cancer research. Her academic training combined molecular biology with translational oncology, giving her a unique foundation to move seamlessly from bench research to clinical applications. She also pursued advanced training in biomarker discovery and molecular diagnostics, enabling her to contribute to projects that merge fundamental discoveries with practical solutions for cancer detection, prognosis, and treatment optimization in a variety of clinical contexts.

Experience

Dr. Erazo’s professional career spans more than 20 completed research projects and leadership in multiple ongoing studies, covering molecular oncology, biomarker discovery, and therapeutic resistance. At MSKCC, she elucidated the mechanism of action of PRMT5 inhibitors and identified MUSASHI-2 as a driver of drug resistance in hematologic malignancies, leading to innovative combination therapy strategies. She developed liquid biopsy-based diagnostics for aggressive prostate cancers and integrated proteomic biomarkers into clinical research pipelines. In her earlier postdoctoral role at Ability Pharmaceuticals, she was instrumental in advancing ABTL-0812 to clinical trials by defining its mechanism and identifying relevant biomarkers. She has partnered with global pharmaceutical and biotech companies, including GlaxoSmithKline, Biodesix Inc., and Guardant Health. Her work also extends to global health initiatives, such as establishing Brazil’s first national referral network for cancer clinical trials with molecular profiling, aiming to address disparities in cancer care and ensure equitable access to precision oncology.

Research Interest

Dr. Erazo’s research focuses on cancer biology, mechanisms of drug resistance, biomarker discovery, and precision oncology. She has a particular interest in hematological malignancies and aggressive solid tumors where therapeutic resistance significantly impacts patient outcomes. Her work applies genome-wide CRISPR synthetic lethal screening, proteomics, and high-throughput drug screening to identify cancer vulnerabilities and inform new treatment strategies. She is advancing diagnostic methods through liquid biopsy technology, enabling early and non-invasive tumor detection and monitoring, with a focus on neuroendocrine prostate cancer. Dr. Erazo also addresses global health inequities by developing clinical trial networks in underrepresented regions and incorporating genetic ancestry into study designs to improve population-specific therapeutic approaches. By combining basic molecular research with translational and clinical applications, she aims to ensure that future cancer therapies and diagnostics are effective across diverse populations and accessible beyond high-resource healthcare settings.

Awards

Dr. Erazo’s scientific achievements have positioned her as a leader in translational cancer research and a nominee for the Molecular Biology Contribution Award. She is recognized for her groundbreaking work on ERK5 signaling, the clinical biomarker development for ABTL-0812, and the identification of MUSASHI-2 as a therapeutic resistance driver. Her contributions to liquid biopsy-based proteomic biomarkers for detecting lineage transformation in prostate cancer have advanced early diagnostic capabilities in precision oncology. She has also been a driving force behind the establishment of Brazil’s first national clinical trial referral network, demonstrating a strong commitment to global health equity. Her work, cited extensively in scientific literature, reflects both scientific rigor and real-world clinical impact. These accomplishments highlight her role as both a laboratory innovator and a global health strategist, whose research has shaped cancer treatment strategies and advanced diagnostic development on an international scale.

Top Noted Publications

Dr. Erazo has authored over 20 peer-reviewed articles in high-impact journals, including Annals of Oncology, Nature Communications, Autophagy, and Clinical Cancer Research. Her research spans mechanistic cancer biology, drug development, and biomarker-driven clinical applications. She has contributed to significant discoveries such as mapping the ERK5 interactome, elucidating the mechanism of action for ABTL-0812, and identifying resistance biomarkers for hematological malignancies. Her publications often emerge from collaborative projects that integrate molecular biology, pharmacology, and clinical trial data, reflecting her multidisciplinary approach to advancing oncology research. The high citation count of her work underscores its influence and the adoption of her findings by researchers and clinicians worldwide. Her studies have informed clinical trial design, therapeutic development, and diagnostic tool implementation, bridging the gap between basic science and patient-centered outcomes in cancer care.

Selected Publications (Single-Line Format)

Title: Erazo T, et al. The new antitumor drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels
Journal: Nature Communications
Cited by 312

Title: Erazo T, et al. Inhibition of PRMT5 in lymphomas overcomes therapeutic resistance via MUSASHI-2 modulation
Journal: Clinical Cancer Research
Cited by 145

Title: Erazo T, et al. ERK5 kinase activity-independent functions in cancer: implications for drug development
Journal: Autophagy
Cited by 110

Title: Erazo T, et al. Blood-based proteomic biomarkers for early detection of lineage plasticity in prostate cancer
Journal: Annals of Oncology
Cited by 35

Title: Erazo T, et al. High-throughput screening of FDA-approved drugs for novel therapeutic combinations in lymphoma
Journal: Molecular Oncology
Cited by 28

Conclusion

Dr. Ingrid Tatiana Erazo’s pioneering research, translational breakthroughs, and commitment to equitable precision oncology position her as an outstanding candidate for the Research for Molecular Biology Contribution Award. Her work exemplifies how rigorous molecular biology can directly shape novel therapeutics, diagnostics, and healthcare systems globally. Awarding her would recognize not only her individual achievements but also her vision for transforming cancer care through innovation and inclusivity.